scispace - formally typeset
W

William O. Rogers

Researcher at Naval Medical Research Center

Publications -  67
Citations -  4989

William O. Rogers is an academic researcher from Naval Medical Research Center. The author has contributed to research in topics: Plasmodium falciparum & Malaria. The author has an hindex of 34, co-authored 65 publications receiving 4604 citations. Previous affiliations of William O. Rogers include Eijkman Institute for Molecular Biology & Albert Einstein College of Medicine.

Papers
More filters
Journal ArticleDOI

Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia.

TL;DR: The results suggest that artesunate-mefloquine combination therapy is beginning to fail in southern Cambodia and that resistance is not confined to the provinces at the Thai-Cambodian border.
Journal ArticleDOI

Characterization of Plasmodium falciparum sporozoite surface protein 2.

TL;DR: Human volunteers immunized with irradiated sporozoites and protected against malaria develop antibody and proliferative T-cell responses to PfSSP2, suggesting that, like PySSP 2, PfS SP2 is a target of protective immunity, and supporting inclusion of PfSSPA2 in a multicomponent malaria vaccine.
Journal ArticleDOI

Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice.

TL;DR: It is demonstrated that optimizing codon usage in DNA vaccines can improve protein expression and consequently the immunogenicity of gene fragments in DNA vaccine plasmids for organisms whosecodon usage differs substantially from that of mammals.
Journal ArticleDOI

Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines

TL;DR: The malaria transmission dynamics in Kassena Nankana district (KND), a site in northern Ghana proposed for testing malaria vaccines, was studied, with timing dependent on the seasonal patterns and intensity of transmission taking into consideration the micro‐geographical differences and vaccine trial objectives.